Please use this identifier to cite or link to this item:
Title: Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis
Author: Campistol Plana, Josep M.
González Duarte, Alejandra
Suhr, Ole B.
Goyal, Sunita
Gandhi, Pritesh J.
Polydefkis, Michael
Sekijima, Yoshiki
O'Riordan, William D.
Yang, Chih-Chao
Ueda, Mitsuharu
Kristen, Arnt V.
Coelho, Teresa
Berk, John L.
Lin, Kon Ping
Vita, Giuseppe
Attarian, Shahram
Planté Bordeneuve, Violaine
Mezei, Michelle M.
Buades, Juan
Brannagan, Thomas H.
Kim, Byoung J.
Oh, Jeeyoung
Parman, Yesim
Hawkins, Philip N.
Solomon, Scott D.
Dyck, Peter J.
Chen, Jihong
Strahs, Andrew L.
Nochur, Saraswathy V.
Sweetser, Marianne T.
Garg, Pushkal P.
Vaishnaw, Akshay K.
Gollob, Jared A.
Keywords: Amiloïdosi
Assaigs clínics
Clinical trials
Issue Date: 5-Jul-2018
Publisher: Massachusetts Medical Society
Abstract: BACKGROUND Patisiran, an investigational RNA interference therapeutic agent, specifically inhibits hepatic synthesis of transthyretin. METHODS In this phase 3 trial, we randomly assigned patients with hereditary transthyretin amyloidosis with polyneuropathy, in a 2:1 ratio, to receive intravenous patisiran (0.3 mg per kilogram of body weight) or placebo once every 3 weeks. The primary end point was the change from baseline in the modified Neuropathy Impairment Score+7 (mNIS+7; range, 0 to 304, with higher scores indicating more impairment) at 18 months. Other assessments included the Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) questionnaire (range, −4 to 136, with higher scores indicating worse quality of life), 10-m walk test (with gait speed measured in meters per second), and modified body-mass index (modified BMI, defined as [weight in kilograms divided by square of height in meters]×albumin level in grams per liter; lower values indicated worse nutritional status). RESULTS A total of 225 patients underwent randomization (148 to the patisiran group and 77 to the placebo group). The mean (±SD) mNIS+7 at baseline was 80.9±41.5 in the patisiran group and 74.6±37.0 in the placebo group; the least-squares mean (±SE) change from baseline was −6.0±1.7 versus 28.0±2.6 (difference, −34.0 points; P<0.001) at 18 months. The mean (±SD) baseline Norfolk QOL-DN score was 59.6±28.2 in the patisiran group and 55.5±24.3 in the placebo group; the least-squares mean (±SE) change from baseline was −6.7±1.8 versus 14.4±2.7 (difference, −21.1 points; P<0.001) at 18 months. Patisiran also showed an effect on gait speed and modified BMI. At 18 months, the least-squares mean change from baseline in gait speed was 0.08±0.02 m per second with patisiran versus −0.24±0.04 m per second with placebo (difference, 0.31 m per second; P<0.001), and the least-squares mean change from baseline in the modified BMI was −3.7±9.6 versus −119.4±14.5 (difference, 115.7; P<0.001). Approximately 20% of the patients who received patisiran and 10% of those who received placebo had mild or moderate infusion-related reactions; the overall incidence and types of adverse events were similar in the two groups. CONCLUSIONS In this trial, patisiran improved multiple clinical manifestations of hereditary transthyretin amyloidosis.
Note: Reproducció del document publicat a:
It is part of: New England Journal of Medicine, 2018, vol. 379, num. 1, p. 11-21
Related resource:
ISSN: 0028-4793
Appears in Collections:Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
681162.pdf366.83 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.